SCHEMBL5340336

SCHEMBL5340336

CC(C)(C)OC(=O)N1CCN(c2ccccc2NS(=O)(=O)CCCCl)CC1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
STS P08842 2/20 0.44
ACHE P22303 1/20 0.43
BACE1 P56817 2/20 0.43
CKS1B P61024 1/20 0.42
SKP1 P63208 1/20 0.42
SKP2 Q13309 1/20 0.42
NAMPT P43490 1/20 0.41
CCNK O75909 1/20 0.41
CCNA2 P20248 1/20 0.41
CDK2 P24941 1/20 0.41
CCND3 P30281 1/20 0.41
CDK9 P50750 1/20 0.41
CDK6 Q00534 1/20 0.41
ALDH1A1 P00352 3/20 0.41
NPSR1 Q6W5P4 3/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
TSHR P16473 1/20 0.41
TGFBR1 P36897 1/20 0.41
SCD O00767 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5338065 0.91 STS (0.44) STSACHEBACE1CKS1BSKP1
SCHEMBL5336031 0.87 STS (0.48) STSACHEBACE1CKS1BSKP1
SCHEMBL5340137 0.83 STS (0.61) STSACHEBACE1CKS1BSKP1
SCHEMBL5333872 0.83 ACHE (0.48) ACHEBACE1CKS1BSKP1SKP2
SCHEMBL4513123 0.82 NPY5R (0.48) STSBACE1CKS1BSKP1SKP2
SCHEMBL5334602 0.80 BACE1 (0.46) STSBACE1CKS1BSKP1SKP2
SCHEMBL4677962 0.80 MEN1 (0.44) STSBACE1NPSR1MEN1KMT2A
SCHEMBL14387753 0.79 BACE1 (0.46) STSACHEBACE1CKS1BSKP1
SCHEMBL5336255 0.79 MCOLN3 (0.62) STSMEN1KMT2ATGFBR1
SCHEMBL6603122 0.78 GPR119 (0.46) STSACHEBACE1CKS1BSKP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7291619-B2 Melanocortin receptor agonists ELI LILLY AND COMPANY (US) 2007-11-06 US disclosed
EP-1368340-B1 PIPERAZINE DERIVATIVES AS MELANOCORTIN RECEPTOR AGONISTS LILLY CO ELI (US) 2005-08-10 EP disclosed
US-20040092507-A1 Melanocortin receptor agonists ELI LILLY AND COMPANY 2004-05-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040092507-A1 Melanocortin receptor agonists MC1R, MC4R, MC5R STS 2096/4885ACHE 3483/4885BACE1 4081/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.